Jacobs Levy Equity Management Inc. grew its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 35.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 566,328 shares of the biopharmaceutical company's stock after acquiring an additional 147,438 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.90% of MacroGenics worth $1,863,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Wasatch Advisors LP raised its stake in shares of MacroGenics by 3.4% during the third quarter. Wasatch Advisors LP now owns 2,535,802 shares of the biopharmaceutical company's stock valued at $8,343,000 after acquiring an additional 84,005 shares in the last quarter. PDT Partners LLC raised its stake in shares of MacroGenics by 44.5% during the third quarter. PDT Partners LLC now owns 160,039 shares of the biopharmaceutical company's stock valued at $527,000 after acquiring an additional 49,288 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of MacroGenics during the third quarter valued at approximately $297,000. Vestal Point Capital LP raised its stake in shares of MacroGenics by 3.8% during the third quarter. Vestal Point Capital LP now owns 830,000 shares of the biopharmaceutical company's stock valued at $2,731,000 after acquiring an additional 30,000 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in shares of MacroGenics by 374.4% during the third quarter. BNP Paribas Financial Markets now owns 90,779 shares of the biopharmaceutical company's stock valued at $299,000 after acquiring an additional 71,643 shares in the last quarter. Institutional investors own 96.89% of the company's stock.
NASDAQ MGNX opened at $3.50 on Friday. The firm's fifty day simple moving average is $3.70 and its two-hundred day simple moving average is $3.94. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88. The firm has a market capitalization of $219.66 million, a P/E ratio of -2.22 and a beta of 2.04.
Several analysts have recently weighed in on the stock. StockNews.com raised shares of MacroGenics from a "sell" rating to a "buy" rating in a research note on Sunday, November 10th. JMP Securities lowered shares of MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday, November 7th. HC Wainwright reissued a "neutral" rating and set a $4.00 price objective on shares of MacroGenics in a report on Wednesday, November 6th. Evercore ISI raised shares of MacroGenics to a "strong-buy" rating in a report on Monday, September 16th. Finally, Citigroup cut their price objective on shares of MacroGenics from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, August 15th. Eight investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $7.63.
Check Out Our Latest Report on MacroGenics
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider MacroGenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.
While MacroGenics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.